Table 5.

Base case values of epidemiologic parameters in cost-effectiveness studies of routine testing for Lynch Syndrome (LS) in patients with colorectal cancer (CRC) that relate to asymptomatic mutation carriers.

Study	# Relatives Tested per Proband	% Relatives Testing Positive for Mutation	Uptake of Prevention among Mutation Carriers	Reduction in risk of CRC with LS Surveillance	Weighted Incidence of First CRC in Absence of Adherence to Prevention	Difference in Case-Fatality Rate of CRC in LS Relative to Non-LS Patients in Absence of Prevention
Mvundura et al. [32]	2.1	45%	79%	62%	41.3%—unadjusted	24%
Ladabaum et al. [31] & Wang et al. [33]	4	50%	80%	58%	46%–54% by age 70	25%–30%
Sie et al. [34]	8	39%	88%	63%	3.5% per year	NR
Snowsill et al. [29,35]	2.1	44%	80%	61%	43.5%–46.4%	21%
Severin et al. [14]	1.1	50%	81.8%	52%	42%—unadjusted 35.6%—adjusted	33%
Barzi et al. [30]	2.6	Not stated	60%–80%	56%	46%–54% by age 70	NR

NR: Not reported.